Drugs / TmPSMA-02 CAR T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06046040 | Jan 2024 → Jan 2027 expected | prostate carcinoma | University of Pennsylvania | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TmPSMA-02 CAR T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06046040 ↗ |
| Modality | Cell therapy | “TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector” NCT06046040 ↗ |
| Route | Intravenous | “via IV infusion” NCT06046040 ↗ |